(Q39739238)

English

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

0 references

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

7

object named as

Maria Buti

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Vincent Di Martino

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Carine Richou

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Jean-Paul Cervoni

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Jose M Sanchez-Tapias

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Donald M Jensen

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Alessandra Mangia

6

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Frances Sheppard

8

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Peter Ferenci

9

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Thierry Thévenot

10

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

0 references

publication date

19 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

789-800

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Meta-analyses of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24480

21 January 2018

Identifiers

10.1002/HEP.24480

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39739238&oldid=2089859549"